top of page

Towards a new drug

NMR-BIO's new project, Alp'Helix, aims to carry out a feasibility study to develop MaxLZ, a future anti-cancer drug targeting the c-Myc protein involved in 70% of cancers. This molecule will be optimized to offer the best possible cell penetration, stability and selectivity properties, with the aim of improving patients' quality of life.

For more infomation please consult ALP'HELIX website.

bottom of page